Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit by Ghislat, Ghita et al.
biomolecules
Article
Identification and Validation of Carbonic Anhydrase
II as the First Target of the Anti-Inflammatory
Drug Actarit
Ghita Ghislat 1,*, Taufiq Rahman 2 and Pedro J. Ballester 3,4,5,6,*
1 Centre d’Immunologie de Marseille-Luminy, Inserm, U1104, CNRS UMR7280, F-13288 Marseille, France
2 Department of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK; mtur2@cam.ac.uk
3 Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, F-13009 Marseille, France
4 CNRS, UMR7258, F-13009 Marseille, France
5 Institut Paoli-Calmettes, F-13009 Marseille, France
6 Aix-Marseille University, UM 105, F-13284 Marseille, France
* Correspondence: gghislat1@gmail.com (G.G.); pedro.ballester@inserm.fr (P.J.B.)
Received: 26 October 2020; Accepted: 16 November 2020; Published: 19 November 2020 
Abstract: Background and purpose: Identifying the macromolecular targets of drug molecules
is a fundamental aspect of drug discovery and pharmacology. Several drugs remain without
known targets (orphan) despite large-scale in silico and in vitro target prediction efforts.
Ligand-centric chemical-similarity-based methods for in silico target prediction have been found to
be particularly powerful, but the question remains of whether they are able to discover targets for
target-orphan drugs. Experimental Approach: We used one of these in silico methods to carry out a
target prediction analysis for two orphan drugs: actarit and malotilate. The top target predicted for
each drug was carbonic anhydrase II (CAII). Each drug was therefore quantitatively evaluated for
CAII inhibition to validate these two prospective predictions. Key Results: Actarit showed in vitro
concentration-dependent inhibition of CAII activity with submicromolar potency (IC50 = 422 nM)
whilst no consistent inhibition was observed for malotilate. Among the other 25 targets predicted
for actarit, RORγ (RAR-related orphan receptor-gamma) is promising in that it is strongly related
to actarit’s indication, rheumatoid arthritis (RA). Conclusion and Implications: This study is a
proof-of-concept of the utility of MolTarPred for the fast and cost-effective identification of targets
of orphan drugs. Furthermore, the mechanism of action of actarit as an anti-RA agent can now be
re-examined from a CAII-inhibitor perspective, given existing relationships between this target and
RA. Moreover, the confirmed CAII-actarit association supports investigating the repositioning of
actarit on other CAII-linked indications (e.g., hypertension, epilepsy, migraine, anemia and bone,
eye and cardiac disorders).
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Bullet Point Summary
What Is Already Known:
• Computational target prediction methods complement and/or guide experimental approaches to
characterise the polypharmacology of drugs.
• Ligand-centric chemical-similarity-based methods (e.g., MolTarPred, freely available at http:
//moltarpred.marseille.inserm.fr/) have been found to be particularly powerful.
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What This Study Adds:
• Experimental confirmation of MolTarPred prediction of CAII as a target of Actarit with a
mid-nanomolar IC50.
• A proof-of-concept of MolTarPred’s utility for target-orphan drugs, providing other plausible
target predictions for actarit (e.g., RORγ).
Clinical Significance:
• The CAII-actarit association sheds light into its mechanism of action as a drug for RA
(rheumatoid arthritis).
• Repositioning of actarit can now be investigated for other CAII-linked indications.
1. Introduction
Discovering the molecular targets of a molecule is important for its potential use as a drug [1,2].
For example, knowing the targets of a drug lead with phenotypic activities is useful to position the lead
on a given indication or to identify its potential toxicities. For drugs already approved for clinical use,
discovering a new target permits improving our understanding of the mechanism of action of the drug
or even repositioning it into an unexpected indication associated with that target.
Studies including reviews of computational methods for target prediction have been published [3,4].
These methods have shown their utility for tackling these problems, both retrospectively [5,6] and
prospectively [7–9]. An early example of these methods is the Similarity Ensemble Approach (SEA),
which constructs a statistical model for each considered target and uses the ensemble of models to
predict which targets interact with the investigated molecule.
SEA has been prospectively applied to de-orphanize drugs without known protein targets [7].
More concretely, these authors analysed a set of 1431 world-wide approved drugs. They found that
1079 of these drugs have known targets in bioactivity databases such as ChEMBL. The remaining
352 drugs were analysed with SEA, which managed to identify targets for 308 of these drugs
(mostly the SEA-suggested target could be verified in the literature, but also experimentally confirmed
in some cases). Despite these efforts, targets could not be found for a set of 41 drugs listed in their
Table S4 [7].
Methods based on other principles may be able to provide useful predictions for these hard-to-predict
target-orphan drugs. In particular, target prediction methods based on chemical similarity have been
found to be particularly powerful [6]. We developed MolTarPred [4], a -similarity-based method able to
predict more than 4500 protein targets, and made it freely available as a webserver [10]. This version of
MolTarPred has recently predicted new targets for mebendazole and nocodazole [9]. These predicted
targets were confirmed in vitro: mebendazole inhibit MAPK14 with an IC50 of 104 nM and nocodazole
inhibit ABL1 with an IC50 of 78 nM [9]. Although several targets were already known for these two
anti-helminthic drugs, the discovery of their potent activity against these cancer targets led to a better
explanation of their anti-glioma properties [9].
Here we present a proof-of-concept study showing that MolTarPred can also be useful with
hard-to-predict target-orphan drugs. In particular, MolTarPred revealed that one of these target-orphan
drugs (actarit) has potent activity against human carbonic anhydrase II (CAII). This discovery may be
helpful to understand the mechanism of action of actarit in rheumatoid arthritis (RA) and opens the
door to repositioning this anti-inflammatory drug to other CAII-linked indications.
2. Materials and Methods
2.1. MolTarPred (Molecular Target Prediction)
MolTarPred is a user-friendly web tool for predicting the targets of small organic molecules [10].
In a nutshell, MolTarPred calculates the similarities between the query molecule (i.e., the molecule
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for which predicted targets are sought after) and many thousands of molecules (the knowledgebase),
each knowledgebase molecule with at least one target annotated. Then, each target annotated in the
10 most similar molecules is predicted as a target of the considered query molecule. MolTarPred
provides an intuitive estimate of the reliability of each target predicted for a given query molecule [10],
which also has the advantage of being validated [4]. The reliability of a predicted target is the number
of top hits that have that target annotated, thus this metric ranges from 1 (minimum reliability) to
10 (maximum reliability). This ligand-centric approach provides by construction the maximum coverage
of target space for a given dataset [4]. The first version (v1) of this tool exploited a knowledgebase with
184,912 molecules retrieved from release 20 of the ChEMBL database [11] and thus were annotated
with 3046 single-protein targets (a molecule is annotated with a target if the Ki, Kd, IC50 or EC50 of
the pair is lower than 10 µM). The second version (v2) of MolTarPred is the current version online
(http://moltarpred.marseille.inserm.fr/) and that was thoroughly described in a recent publication [10].
MolTarPred v2 exploits a much larger knowledgebase than v1 comprising 607,659 small-molecule
ligands annotated with at least one of 4553 protein targets [10]. A comprehensive description of how
to use MolTarPred and interpret its results has already been published [10], with two previous papers
developing and validation its working principles [4,5].
2.2. CAII Activity Assay
CAII activity was measured using Wilbur and Anderson’s electrometric method [12]. Briefly,
the time required for a saturated carbon dioxide solution to lower the pH of a 20 mM Trizma buffer
from 8.3 to 6.3 at 0 ◦C was determined without (T0) or with 0.02 mg/mL of CAII +/− inhibitors (T) to
calculate the Wilbur-Anderson unit (2 × (T0 − T))/T of each sample. The activity of CAII was assessed
as Wilbur-Anderson units/mg of CA II in each reaction.
2.3. Materials
The following reagents were purchased from Sigma-Aldrich (Saint-Quentin-Fallavier, France):
recombined human carbonic anhydrase II (C6165), Trizma buffer (T1501) and pH 4, 7 and 10 standard
buffers (B5020, B4770 and B4895). Actarit (95% purity) and malotilate (95% purity) were purchased
from Molport (MolPort-002-468-862 and MolPort-006-131-867, respectively (Molprot, Riga, Latvia),
and were supplied by Enamine Ltd. (EN300-13165, Enamine Ltd., Kiev, Ukraine) and AK Scientific, Inc.
(C865, AK Scientific, Inc., Union City, CA, USA), respectively.
3. Results
The analysis of the 41 target-orphan drugs was carried out using MolTarPred v1, before v2
was available. More concretely, for this proof-of-concept, we non-exhaustively searched for a target
predicted on at least 2 of the 41 drugs. This strategy is intended to optimise our resources, as in vitro
evaluation of target predictions can be technically very demanding due to the need for a distinct
experimental approach per target. For example, the evaluation of five molecules predicted to have the
same target is much easier than that of one molecule predicted to interact with five targets, despite each
case requiring the evaluation of five ligand-target activity values. This is because the former case
requires setting up only 1 assay while the latter needs having 5 different assays in place. On the
other hand, we were interested in target predictions with the highest estimated reliability for the drug
to maximize the likelihood of the predicted target being a true target. Lastly, we requested predicted
targets linked to disease indications via drugs approved for patient use. In this way, any new molecular
target would not only provide clues about the mechanism of action of the target-orphan drug, but also
unveil new repositioning opportunities for the drug.
MolTarPred v1 revealed human CAII as a target with the sought characteristics, which was
predicted for two of the target-orphan drugs: actarit and malotilate. Actarit is a disease-modifying
anti-rheumatic drug, or DMARD [13,14], that can be orally administered [15]. Figure 1 shows the
targets predicted for actarit by MolTarPred v1, with CAII being predicted with the highest reliability
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(Figure 1A). CAII was predicted with reliability 3, as 3 of the top 10 most similar molecules to actarit
were annotated with this target (Figure 1B,C). A target predicted with reliability 3 is estimated to
be a true target of the drug 41.7% of the time [4]. To experimentally validate whether or not CAII
could be a target for actarit, we quantitatively evaluated actarit against the activity of recombinant
human CAII in vitro following the established method [12]. As observed in Figure 2, actarit showed
concentration-dependent inhibition of CAII activity with submicromolar potency (IC50 = 422 nM).
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CAII was also the target predicted with highest reliability for malotilate, an orally-administrated drug
for the treatment of hepatic diseases [16]. Figure 3 shows that the targets predicted for malotilate
by MolTarPred v1. CAII were predicted with reliability 7 (Figure 3A), as 7 of the top 10 most
similar molecules to malotilate were annotated with this target (Figure 3B,C). To validate the observed
CAII-malotilate prediction, we tested malotilate against human CAII activity using an aforementioned
quantitative approach, but observed no consistent inhibition in vitro (Figure 4). The lack of a dose-response
curve meant that its IC50 could not be calculated.
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4. Discussion and Conclusions
Despite substantial research on actarit, e.g., exploring its clinical phenotype [15,17], improving its
administration [18,19] or enhancing its stability within the organism [20,21], no molecular target
of this drug has previously been found. MolTarPred v1 was hence able to discover the first target
for actarit where SEA could not [7]. Running the current version of SEA (http://sea.bkslab.org/)
on actarit returns CAII as the 74th predicted target and not being ranked sufficiently high seems
the reason why this target-drug association was missed. ChEMBL recently supplements their
compiled measurements with in silico target predictions [22], which also missed this target of
actarit (https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1885632). This shows that
MolTarPred can complement these methods for in silico target prediction analysis.
Relationships between some carbonic anhydrase (CA) proteins and RA have been reported.
Pan-CA inhibitors, including CAII, were previously shown to be efficient for the treatment of
RA [23,24]. CAIII and CAIV autoantibodies, which inhibit these CA activities, were identified as
diagnostic markers of RA [25,26]. In line with these observations, CAII autoantibodies were as well
found in high amounts in RA patients where a correlation with oxidative stress was observed [27].
Thus, CAII may be the primary target of actarit for the treatment of RA. CAII is a zinc-dependent
metalloenzyme. The carboxylate group of actarit may serve as a zinc-chelating agent blocking the
catalytinc activity of CAII. We stipulate that the discovery of CAII as a molecular target of actarit will help
to gain a better understanding of the mechanism of action of this drug. On the other hand, the molecular
function of CAII can have broader applications. This enzyme target catalyses the reversible hydration
of carbon dioxide, which dissociates into protons, and bicarbonate ions in a widespread fashion
among tissues and cell compartment across many organisms [28]. A balance between carbon dioxide
and protons/bicarbonate is essential for a plethora of physiological processes and excess of insoluble
protons/bicarbonate may destabilize physiological pH. Thus, dysfunctions in the enzymatic activity or
expression level of CAII have been associated with a range of diseases, from anemia [29] and bone,
eye and cardiac disorders [30] to various cancers [31]. Some examples of FDA-approved CAII inhibitors
are brinzolamide to treat elevated intraocular pressure, chlorothiazide indicated for hypertension and
topiramate to treat epilepsy and migraines. Therefore, our study could also contribute to expand the
indications of actarit. The of actarit, as a human-safe CAII inhibitor can now be investigated in the
same indications associated with CAII.
MolTarPred also has the advantage of offering interpretability for its predictions. For example,
the most similar molecule to actarit was CHEMBL112, also known as paracetamol (Figure 1B), with both
chemical structures only differing in a terminal functional group (Figure 1C). Paracetamol has moderate
CAII activity with a Ki of 6.2 µM [32]. This means that MolTarPred v1 was able to identify a new
CAII inhibitor with about 15-fold higher potency (IC50 of 422 nM) than its closest top hit and that
the functional group substitution (carboxymethyl in actarit, hydroxyl in paracetamol) is the cause of
such potency enhancement. Furthermore, given the high similarity between actarit and paracetamol,
it is likely that actarit also has similar activity to at least some of the other targets of paracetamol.
This merits further investigation and might lead to further repositioning opportunities.
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Like actarit, malotilate was classified as a hard-to-predict target-orphan drug [7] and the ChEMBL
database does not report any known target either (https://www.ebi.ac.uk/chembl/compound_report_
card/CHEMBL1697754). However, there is a 30-year-old study reporting an IC50 of 4.7 µM with
5-lipoxygenase [33]. This target was not only missed by SEA, but also MolTarPred and the ChEMBL
method. A possible reason is that the activity of this association is close to the threshold of activity of
these methods (10 µM).
By comparing Figures 1 and 3, one can see that CAII was predicted for malotilate with higher
reliability than for actarit, yet no CAII inhibition was induced by malotilate. There are several factors that
could explain this opposite outcome. First, higher reliability only confers a higher likelihood of being a
true target [4], so while less likely the result is entirely possible. Second, target inference was carried
out from less similar top hits in malotilate (similarity scores between 32% and 36%) than in Actarit
(similarity scores ranging from 45% to 54%). By the molecular similarity principle [34], the more similar
the molecules are, the higher the likelihood that they hit the same targets. Third, malotilate presents
ester groups susceptible to undergo hydrolysis by esterases present in the cytosol, which hints the
possibility of this drug being actually a prodrug, in which case any target prediction method would
need to consider instead its pharmacologically active form after metabolism. Lastly, there are also more
CAII binding sites apart from its active site [35] and hence malotilate could still be binding to CAII
without affecting its enzymatic activity. In other words, malotilate-CAII could not be a false positive.
A way to obtain higher similarities between the chemical structures of a query molecule and
its most similar molecules is employing a larger knowledgebase. This will increase the average
accuracy of the predictions, which may in turn result in other predicted targets worth considering.
For example, if we use instead MolTarPred v2, which has a 3.3-times larger knowledgebase than that
of v1, the target predicted with the highest reliability is now murine nuclear receptor ROR (RAR-related
orphan receptor)-gamma (RORC or RORγ, for short). Figure 5 shows the four top hits supporting
this prediction (reliability 4), with higher similarity scores to actarit (from 55% to 57%) than the top
hits from MolTarPred v1 (from 45% to 54%). None of the molecules that were supporting the CAII
prediction in MolTarPred v1 are among the top 10 hits in MolTarPred v2 (they are now lower in
the ranking) and none of these top 10 hits in MolTarPred v2 are known to bind CAII. As a result,
CAII is not predicted as a target of actarit by MolTarPred v2. This seemingly shocking outcome is
not unexpected. A high rate of false negatives, i.e., low recovery rates, is a well-known limitation of in
silico target prediction, which instead excels at quickly providing target predictions with generally
few false positives [5,6], as it has been the case here. This high-false-negative limitation is largely
due to sparse nature of ligand-target bioactivity data (even in the most comprehensive databases,
only 0.04% of all the possible ligand-target pairs in the knowledgebase have at least one bioactivity
value associated [4]). Given the relatively high similarity of the MolTarPred v2′s top hits to actarit
(Figure 5), each containing a CAII-privileged carboxylate group, it is very likely that at least some of
them will inhibit CAII activity as well, once they are tested in vitro. Updating MolTarPred with any of
these top hits as a CAII inhibitor would lead to CAII being predicted again.
RORγ is largely conserved between mice and humans (88.9% amino acid sequence identity).
The latter, along with the prediction of murine RORγ, strongly suggests that human RORγ could be
another target of actarit, a target that is also related to RA. Indeed, RORγ (the T cell specific isoform
is RORγt) is a key transcription factor driving Th17 cell differentiation leading to subsequent production
of IL-17A and few other pro-inflammatory cytokines as well as triggering NLRP3 inflammasome
activity [36,37]. In addition, hyperactive Th17 cells have been implicated in the pathology of
several autoimmune diseases, including multiple sclerosis, RA, psoriasis and Crohn’s disease. [38,39].
Accordingly, genetic ablation of RORγ or its pharmacological inhibition has been shown to be protective
in various animal models of some of these autoimmune diseases [37,40]. Thus, actarit is potentially
repurposable for these autoimmune diseases.
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mechanism of action of actarit as an anti-RA agent can now be re-examined from a CAII-inhibitor 
Fig re . ( ) l ar red v2′s predicted targets for actarit. Ther are 11 predicted targets, one per row,
sorted by ecreasing reliability score. ROR-γ, highlighted in green, appears as target of actarit with a
reliability score of 4. (B) SMILES and similarity scores of the four top hits annotated with the inspected
predicte target (ROR-γ). (C) Chemical structures of the query molecule (actarit; top left) and its top
four ROR-γ-annotated hits listed in (B) to its right and bottom row.
Overall, this study has predicted 26 targets for actarit (15 from Figure 1 plus 11 from Figure 5).
We have evaluated the most reliable prediction in Figure 1, which was found to be correct (CAII-actarit
interact in vitro with an IC50 of 422 nM). This constitutes a proof-of-concept that MolTarPred can
discover targets even for drugs without previously known targets. Furthermore, the mechanism of
action of actarit as an anti-RA agent can now be re-examined from a CAII-inhibitor perspective given
the explained relationships between CA and RA. Moreover, the confirmed CAII-actarit association
supports investigating the repositioning of actarit in CAII-linked indications (e.g., hypertension,
epilepsy, migraine, anemia, bone, eye and cardiac disorders, among others).
The provided target prediction analysis permits others to evaluate any of these 25 potential targets
of actarit. This is worthwhile because a small-molecule drug hits over 11 targets with an IC50 better
than 10 µM on average [4] and thus Actarit is likely to hit several other targets. Particularly promising
is the predicted RORγ-actarit association, given that RORγ is strongly related to auto-immune diseases,
including RA [36].
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